Gene Expression and Genome Wide Association Study on remission of asthma

Gene Expression and Genome Wide Association Study on remission of asthma - Gene Expression and GWAS on remission of asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40066

Enrollment

277

Registered

2012-11-16

Start date

2012-11-16

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma hyperresponsivenes

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Roorda cohort and the DAG cohort (asthma) 1. Age 18 years or older 2. Previous diagnosis of asthma 3. Bronchial hyperresponsiveness in childhood (Roorda Cohort) 4. In clinical or complete remission of asthma (DAG cohort) NORM study (healthy) 1. Age 18 years or older 2. FEV1 pre bronchodilator > 80% predicted 3. No bronchial hyperresponsiveness; PC20 metacholinebromide >32 mg/ml 4. Never diagnosed with asthma

Exclusion criteria

Exclusion criteria: For all cohorts 1. Presence of serious concomitant diseases (Cancer, Cardiovascular disorders) 2. Pregnancy Additional exclusion criterium for metacholine challenge testing: 3. FEV1 below 1.2 L

Design outcomes

Primary

Measure	Time frame
The main outcome parameter is the expression level of mRNA. These expression levels will be compared between patients in complete asthma remission, clinical asthma remission, no asthma remission and healthy controls.	—

Secondary

Measure	Time frame
1. The genetic variation at DNA-level will be used to perform a GWAs study on the presence of asthma remission. 2. Association of IL1RL1 gene variation, with IL1RL1 T lymphocyte expression with and without IL-33 stimulation. 3. Investigate the differences in DNA-methylation between asthmatics and patients in clinical or complete remission 4. Cultivate nasal epithelial cells for hypothesis-testing in functional studies based on results of the genetic expression and association analyses. 5. To compare the small airway parameters Scond and Sacin between patients in complete remission of asthma, clinical remission of asthma and patients with current asthma.	—

Measure

Time frame

1. The genetic variation at DNA-level will be used to perform a GWAs study on the presence of asthma remission. 2. Association of IL1RL1 gene variation, with IL1RL1 T lymphocyte expression with and without IL-33 stimulation. 3. Investigate the differences in DNA-methylation between asthmatics and patients in clinical or complete remission 4. Cultivate nasal epithelial cells for hypothesis-testing in functional studies based on results of the genetic expression and association analyses. 5. To compare the small airway parameters Scond and Sacin between patients in complete remission of asthma, clinical remission of asthma and patients with current asthma.

—

Countries

Netherlands

Outcome results